Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paul G. Leonard is active.

Publication


Featured researches published by Paul G. Leonard.


Proceedings of the National Academy of Sciences of the United States of America | 2010

H-NS forms a superhelical protein scaffold for DNA condensation

Stefan T. Arold; Paul G. Leonard; Gary N. Parkinson; John E. Ladbury

The histone-like nucleoid structuring (H-NS) protein plays a fundamental role in DNA condensation and is a key regulator of enterobacterial gene expression in response to changes in osmolarity, pH, and temperature. The protein is capable of high-order self-association via interactions of its oligomerization domain. Using crystallography, we have solved the structure of this complete domain in an oligomerized state. The observed superhelical structure establishes a mechanism for the self-association of H-NS via both an N-terminal antiparallel coiled-coil and a second, hitherto unidentified, helix-turn-helix dimerization interface at the C-terminal end of the oligomerization domain. The helical scaffold suggests the formation of a H-NS:plectonemic DNA nucleoprotein complex that is capable of explaining published biophysical and functional data, and establishes a unifying structural basis for coordinating the DNA packaging and transcription repression functions of H-NS.


Bioorganic & Medicinal Chemistry Letters | 2005

Identification of potent and selective MMP-13 inhibitors.

Alessia Petrocchi; Elisabetta Leo; Naphtali Reyna; Matthew M. Hamilton; Xi Shi; Connor A. Parker; Faika Mseeh; Jennifer Bardenhagen; Paul G. Leonard; Jason B. Cross; Sha Huang; Yongying Jiang; Mario G. Cardozo; Giulio Draetta; Joseph R. Marszalek; Carlo Toniatti; Philip Jones; Richard T. Lewis

Structure based design of a novel class of aminopyrimidine MTH1 (MutT homolog 1) inhibitors is described. Optimization led to identification of IACS-4759 (compound 5), a sub-nanomolar inhibitor of MTH1 with excellent cell permeability and good metabolic stability in microsomes. This compound robustly inhibited MTH1 activity in cells and proved to be an excellent tool for interrogation of the utility of MTH1 inhibition in the context of oncology.


Nature Medicine | 2016

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.

Yi Du; Hirohito Yamaguchi; Yongkun Wei; Jennifer L. Hsu; Hung Ling Wang; Yi Hsin Hsu; Wan Chi Lin; Wen Hsuan Yu; Paul G. Leonard; Gilbert R. Lee; Mei Kuang Chen; Katsuya Nakai; Ming Chuan Hsu; Chun Te Chen; Ye Sun; Yun Wu; Wei Chao Chang; Wen Chien Huang; Chien Liang Liu; Yuan Ching Chang; Chung-Hsuan Chen; Morag Park; Philip Jones; Gabriel N. Hortobagyi; Mien Chie Hung

Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer, in clinical trials. One PARP inhibitor, olaparib (Lynparza, AstraZeneca), was recently approved by the FDA to treat ovarian cancer with mutations in BRCA genes. BRCA1 and BRCA2 have essential roles in repairing DNA double-strand breaks, and a deficiency of BRCA proteins sensitizes cancer cells to PARP inhibition. Here we show that the receptor tyrosine kinase c-Met associates with and phosphorylates PARP1 at Tyr907 (PARP1 pTyr907 or pY907). PARP1 pY907 increases PARP1 enzymatic activity and reduces binding to a PARP inhibitor, thereby rendering cancer cells resistant to PARP inhibition. The combination of c-Met and PARP1 inhibitors synergized to suppress the growth of breast cancer cells in vitro and xenograft tumor models, and we observed similar synergistic effects in a lung cancer xenograft tumor model. These results suggest that the abundance of PARP1 pY907 may predict tumor resistance to PARP inhibitors, and that treatment with a combination of c-Met and PARP inhibitors may benefit patients whose tumors show high c-Met expression and who do not respond to PARP inhibition alone.


Proceedings of the National Academy of Sciences of the United States of America | 2013

Phosphorylation-dependent conformational changes and domain rearrangements in Staphylococcus aureus VraR activation

Paul G. Leonard; Dasantila Golemi-Kotra; Ann M. Stock

Staphylococcus aureus VraR, a vancomycin-resistance-associated response regulator, activates a cell-wall–stress stimulon in response to antibiotics that inhibit cell wall formation. X-ray crystal structures of VraR in both unphosphorylated and beryllofluoride-activated states have been determined, revealing a mechanism of phosphorylation-induced dimerization that features a deep hydrophobic pocket at the center of the receiver domain interface. Unphosphorylated VraR exists in a closed conformation that inhibits dimer formation. Phosphorylation at the active site promotes conformational changes that are propagated throughout the receiver domain, promoting the opening of a hydrophobic pocket that is essential for homodimer formation and enhanced DNA-binding activity. This prominent feature in the VraR dimer can potentially be exploited for the development of novel therapeutics to counteract antibiotic resistance in this important pathogen.


Proceedings of the National Academy of Sciences of the United States of America | 2011

Structural basis for the sequence-specific recognition of human ISG15 by the NS1 protein of influenza B virus

Rongjin Guan; Li Chung Ma; Paul G. Leonard; Brendan R. Amer; Haripriya Sridharan; Chen Zhao; Robert M. Krug; Gaetano T. Montelione

Interferon-induced ISG15 conjugation plays an important antiviral role against several viruses, including influenza viruses. The NS1 protein of influenza B virus (NS1B) specifically binds only human and nonhuman primate ISG15s and inhibits their conjugation. To elucidate the structural basis for the sequence-specific recognition of human ISG15, we determined the crystal structure of the complex formed between human ISG15 and the N-terminal region of NS1B (NS1B-NTR). The NS1B-NTR homodimer interacts with two ISG15 molecules in the crystal and also in solution. The two ISG15-binding sites on the NS1B-NTR dimer are composed of residues from both chains, namely residues in the RNA-binding domain (RBD) from one chain, and residues in the linker between the RBD and the effector domain from the other chain. The primary contact region of NS1B-NTR on ISG15 is composed of residues at the junction of the N-terminal ubiquitin-like (Ubl) domain and the short linker region between the two Ubl domains, explaining why the sequence of the short linker in human and nonhuman primate ISG15s is essential for the species-specific binding of these ISG15s. In addition, the crystal structure identifies NS1B-NTR binding sites in the N-terminal Ubl domain of ISG15, and shows that there are essentially no contacts with the C-terminal Ubl domain of ISG15. Consequently, NS1B-NTR binding to ISG15 would not occlude access of the C-terminal Ubl domain of ISG15 to its conjugating enzymes. Nonetheless, transfection assays show that NS1B-NTR binding of ISG15 is responsible for the inhibition of interferon-induced ISG15 conjugation in cells.


PLOS ONE | 2014

The human orphan nuclear receptor tailless (TLX, NR2E1) is druggable

Cindy Benod; Rosa Villagomez; Carly S. Filgueira; Peter K. Hwang; Paul G. Leonard; Guillaume Poncet-Montange; Senapathy Rajagopalan; Robert J. Fletterick; Jan Åke Gustafsson; Paul Webb

Nuclear receptors (NRs) are an important group of ligand-dependent transcriptional factors. Presently, no natural or synthetic ligand has been identified for a large group of orphan NRs. Small molecules to target these orphan NRs will provide unique resources for uncovering regulatory systems that impact human health and to modulate these pathways with drugs. The orphan NR tailless (TLX, NR2E1), a transcriptional repressor, is a major player in neurogenesis and Neural Stem Cell (NSC) derived brain tumors. No chemical probes that modulate TLX activity are available, and it is not clear whether TLX is druggable. To assess TLX ligand binding capacity, we created homology models of the TLX ligand binding domain (LBD). Results suggest that TLX belongs to an emerging class of NRs that lack LBD helices α1 and α2 and that it has potential to form a large open ligand binding pocket (LBP). Using a medium throughput screening strategy, we investigated direct binding of 20,000 compounds to purified human TLX protein and verified interactions with a secondary (orthogonal) assay. We then assessed effects of verified binders on TLX activity using luciferase assays. As a result, we report identification of three compounds (ccrp1, ccrp2 and ccrp3) that bind to recombinant TLX protein with affinities in the high nanomolar to low micromolar range and enhance TLX transcriptional repressive activity. We conclude that TLX is druggable and propose that our lead compounds could serve as scaffolds to derive more potent ligands. While our ligands potentiate TLX repressive activity, the question of whether it is possible to develop ligands to de-repress TLX activity remains open.


Biochemistry | 2012

Identification of a Hydrophobic Cleft in the LytTR Domain of AgrA as a Locus for Small Molecule Interactions That Inhibit DNA Binding.

Paul G. Leonard; Ian F. Bezar; David Sidote; Ann M. Stock

The AgrA transcription factor regulates the quorum-sensing response in Staphylococcus aureus, controlling the production of hemolysins and other virulence factors. AgrA binds to DNA via its C-terminal LytTR domain, a domain not found in humans but common in many pathogenic bacteria, making it a potential target for antimicrobial development. We have determined the crystal structure of the apo AgrA LytTR domain and screened a library of 500 fragment compounds to find inhibitors of AgrA DNA binding activity. Using nuclear magnetic resonance, the binding site for five compounds has been mapped to a common locus at the C-terminal end of the LytTR domain, a site known to be important for DNA binding activity. Three of these compounds inhibit AgrA DNA binding. These results provide the first evidence that LytTR domains can be targeted by small organic compounds.


Molecular Microbiology | 2009

Investigation of the self-association and hetero-association interactions of H-NS and StpA from Enterobacteria

Paul G. Leonard; Shusuke Ono; Jayesh Gor; Stephen J. Perkins; John E. Ladbury

The nucleoid‐associated protein H‐NS and its paralogue StpA are global regulators of gene expression and form an integral part of the protein scaffold responsible for DNA condensation in Escherichia coli and Salmonella typhimurium. Although protein oligomerization is a requirement for this function, it is not entirely understood how this is accomplished. We address this by reporting on the self‐association of H‐NS and its hetero‐association with StpA. We identify residues 1–77 of H‐NS as being necessary and sufficient for high‐order association. A multi‐technique‐based approach was used to measure the effects of salt concentration on the size distribution of H‐NS and the thermal stability of H‐NS and StpA dimers. The thermal stability of the StpA homodimer is significantly greater than that of H‐NS1−74. Investigation of the hetero‐association of H‐NS and StpA proteins suggested that the association of H‐NS with StpA is more stable than the self‐association of either H‐NS or StpA with themselves. This provides a clear understanding of the method of oligomerization of these important proteins in effecting DNA condensation and reveals that the different associative properties of H‐NS and StpA allow them to perform distinct, yet complementary roles in the bacterial nucleoid.


Nature Structural & Molecular Biology | 2014

Competition between Grb2 and Plcγ1 for FGFR2 regulates basal phospholipase activity and invasion

Zahra Timsah; Zamal Ahmed; Chi Chuan Lin; Fernando A. Melo; Loren J. Stagg; Paul G. Leonard; Prince V. Jeyabal; Jonathan Berrout; Roger G. O'Neil; Mikhail Bogdanov; John E. Ladbury

FGFR2-expressing human cancer cells with low concentrations of the adaptor protein Grb2 show high prevalence for metastatic outcome. In nonstimulated cells, the SH3 domain (and not the SH2 domains) of Plcγ1 directly competes for a binding site at the very C terminus of FGFR2 with the C-terminal SH3 domain of Grb2. Reduction of Grb2 concentration permits Plcγ1 access to the receptor. Recruitment of Plcγ1 in this way is sufficient to upregulate phospholipase activity. This results in elevated phosphatidylinositol 4,5-bisphosphate turnover and intracellular calcium levels, thus leading to increased cell motility and promotion of cell-invasive behavior in the absence of extracellular receptor stimulation. Therefore, metastatic outcome can be dictated by the constitutive competition between Grb2 and Plcγ1 for the phosphorylation-independent binding site on FGFR2.


Nucleic Acids Research | 2015

A variable DNA recognition site organization establishes the LiaR-mediated cell envelope stress response of enterococci to daptomycin

Milya Davlieva; Yiwen Shi; Paul G. Leonard; Troy A. Johnson; Michael Zianni; Cesar A. Arias; John E. Ladbury; Yousif Shamoo

LiaR is a ‘master regulator’ of the cell envelope stress response in enterococci and many other Gram-positive organisms. Mutations to liaR can lead to antibiotic resistance to a variety of antibiotics including the cyclic lipopeptide daptomycin. LiaR is phosphorylated in response to membrane stress to regulate downstream target operons. Using DNA footprinting of the regions upstream of the liaXYZ and liaFSR operons we show that LiaR binds an extended stretch of DNA that extends beyond the proposed canonical consensus sequence suggesting a more complex level of regulatory control of target operons. We go on to determine the biochemical and structural basis for increased resistance to daptomycin by the adaptive mutation to LiaR (D191N) first identified from the pathogen Enterococcus faecalis S613. LiaRD191N increases oligomerization of LiaR to form a constitutively activated tetramer that has high affinity for DNA even in the absence of phosphorylation leading to increased resistance. Crystal structures of the LiaR DNA binding domain complexed to the putative consensus sequence as well as an adjoining secondary sequence show that upon binding, LiaR induces DNA bending that is consistent with increased recruitment of RNA polymerase to the transcription start site and upregulation of target operons.

Collaboration


Dive into the Paul G. Leonard's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gilbert R. Lee

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Barbara Czako

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

David Maxwell

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Florian Muller

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Naima Hammoudi

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Nikunj Satani

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Ronald A. DePinho

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Federica Pisaneschi

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge